Abstract:Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) pose a severe threat to human health. Our previous research results, as well as those of other research groups, indicated that antibodies (Abs) induced by JEV infection or JEV vaccine vaccination could enhance ZIKV infection in vitro and exacerbate the mortality of ZIKV-infected mice, vice versa, which is known as antibody-dependent enhancement (ADE). Although studies on other flaviviruses revealed that altering the amino acid residues located in the fusion loop (FL) of envelope (E) protein can reduce the level of flavivirus-cross-reactive Abs, thereby abating the ADE of heterologous flavivirus infection, it is unclear whether this strategy is equally applicable to JEV. Methods: In this study, we constructed recombinant adenoviruses and nucleotide-modified mRNA-lipid nanoparticle (LNP) encoding JEV wild-type E protein or E protein mutant (designated as Ad5-JEV-E WT and Ad5-JEV-E mut ; JEV-E WT mRNA-LNP, and JEV-E mut mRNA-LNP). We evaluated the immunogenicity of these vaccine candidates in mice and the capacity of vaccine-immune mouse sera to neutralize JEV infection or mediate ADE of ZIKV infection in vitro and in vivo . Results: Ad5-JEV-E mut or JEV-E mut mRNA-LNP immunization induced ZIKV-cross-reactive Ab response which is dramatically lower than that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The levels of JEV-neutralizing Abs induced by Ad5-JEV-E mut or JEV-E mut mRNA-LNP are comparable to that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The ability of Abs induced by Ad5-JEV-E mut to enhance ZIKV infection in vitro is attenuated as compared with that induced by Ad5-JEV-E WT . Moreover, JEV-E mut mRNA-LNP immunization elicited potent T cell response similar to JEV-E WT mRNA-LNP in mice. Mice immunized with each mRNA-LNP exhibited lower level of serum viral load than the mock-immunized mice post JEV challenge. Mice receiving JEV-E WT mRNA-LNP-immune mouse sera exhibited ADE post ZIKV challenge whereas passively transferred JEV-E mut mRNA-LNP-immune mouse sera did not lead to obvious ADE of ZIKV infection in recipient mice. Most importantly, maternally acquired Abs did not enhance the mortality of 1-day-old neonates born to JEV-E mut mRNA-LNP-immunized mice post ZIKV challenge. Discussion: These results suggest that optimizing the FL sequence of JEV could significantly reduce the level of JEV/ZIKV-cross-reactive Abs and abrogate the ADE of ZIKV infection, providing a promising strategy to develop effective and safety JEV vaccine.

Novel Japanese Encephalitis Virus Ns1-Based Vaccine: Truncated Ns1 Fused With E. Coli Heat Labile Enterotoxin B Subunit

Study of Japanese Encephalitis Virus NS1 Gene and Its Vaccine

Identification of a Protective Epitope in Japanese Encephalitis Virus NS1 Protein.

The A66g Back Mutation in Ns2a of Jev Sa(14)-14-2 Strain Contributes to Production of Ns1 ' Protein and the Secreted Ns1 ' Can Be Used for Diagnostic Biomarker for Virulent Virus Infection

Nanoparticle Vaccine Based on the Envelope Protein Domain III of Japanese Encephalitis Virus Elicits Robust Protective Immune Responses in Mice.

A Novel Recombinant Virus-Like Particles Displaying B and T Cell Epitopes of Japanese Encephalitis Virus Offers Protective Immunity in Mice and Guinea Pigs

Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain

A Molecularly Cloned, Live-Attenuated Japanese Encephalitis Vaccine SA14-14-2 Virus: a Conserved Single Amino Acid in the Ij Hairpin of the Viral E Glycoprotein Determines Neurovirulence in Mice.

Prokaryotic expression of NS1' protein resulted from ribosomal frameshifting in Japanese encephalitis virus and its immunoreactivity

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice

AB5-Type Toxin as a Pentameric Scaffold in Recombinant Vaccines against the Japanese Encephalitis Virus

Monoclonal Antibodies Against NS2B of Japanese Encephalitis Virus

Immunization with Pseudotype Baculovirus Expressing Envelope Protein of Japanese Encephalitis Virus Elicits Protective Immunity in Mice

Protective Immune Responses Induced by an Mrna-Lnp Vaccine Encoding Prm-E Proteins Against Japanese Encephalitis Virus Infection

Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate

NS1' Protein Expression Facilitates Production of Japanese Encephalitis Virus in Avian Cells and Embryonated Chicken Eggs.

Baculovirus Surface Display of E Envelope Glycoprotein of Japanese Encephalitis Virus and Its Immunogenicity of the Displayed Proteins in Mouse and Swine Models.

A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1' formation and contributes to attenuation.

[Generation of Japanese Encephalitis Virus-like Particle Vaccine and Preliminary Evaluation of Its Protective Efficiency].

Construction of Recombinant Pseudorabies Virus Expressing NS1 Protein of Japanese Encephalitis (SA14-14-2) Virus and Its Safety and Immunogenicity.

Enhanced Immune Responses Against Japanese Encephalitis Virus Infection Using Japanese Encephalitis Live-Attenuated Virus Adjuvanted with Montanide GEL 01 ST in Mice